First-in-class targeted therapy has potential for colon cancer
Germany’s Merck KGaA (MRK:DE) announced a licensing agreement with New York-based small molecule developer Inspirna. The agreement is for ompenacrid, a first-in-class SLC6A8 blocker, and will also include other similar follow-on compounds. Omphenacrid is currently being evaluated in a Phase II trial for second-line treatment of certain people with advanced or metastatic colorectal cancer (mCRC). […]